期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 168, 期 2, 页码 296-317出版社
WILEY
DOI: 10.1111/j.1476-5381.2012.02195.x
关键词
endothelin; myocyte; contraction; hypertrophy; calcium; kinase
资金
- BHF [PG/11/12/28717]
- BBSRC
- Biotechnology and Biological Sciences Research Council [BBS/E/B/0000C116, BBS/E/B/0000H326, BBS/E/B/0000H215] Funding Source: researchfish
- British Heart Foundation [PG/11/12/28717] Funding Source: researchfish
- BBSRC [BBS/E/B/0000H326, BBS/E/B/0000H215] Funding Source: UKRI
Endothelin-1 (ET-1) is a critical autocrine and paracrine regulator of cardiac physiology and pathology. Produced locally within the myocardium in response to diverse mechanical and neurohormonal stimuli, ET-1 acutely modulates cardiac contractility. During pathological cardiovascular conditions such as ischaemia, left ventricular hypertrophy and heart failure, myocyte expression and activity of the entire ET-1 system is enhanced, allowing the peptide to both initiate and maintain maladaptive cellular responses. Both the acute and chronic effects of ET-1 are dependent on the activation of intracellular signalling pathways, regulated by the inositol-trisphosphate and diacylglycerol produced upon activation of the ETA receptor. Subsequent stimulation of protein kinases C and D, calmodulin-dependent kinase II, calcineurin and MAPKs modifies the systolic calcium transient, myofibril function and the activity of transcription factors that coordinate cellular remodelling. The precise nature of the cellular response to ET-1 is governed by the timing, localization and context of such signals, allowing the peptide to regulate both cardiomyocyte physiology and instigate disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据